𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine

✍ Scribed by Roberto Cavallaro; Cristina Colombo; Enrico Smeraldi

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
273 KB
Volume
10
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

The aim of this report is to show the results of a pilot, open label treatment programme for resistant schizophrenia in which risperidone was used before clozapine. Thirteen DSM I11 R, drug resistant schizophrenics were treated with risperidone p.0. at doses up to 16 mg/day for three months. Clinical assessment was performed before and after 1,2 and 3 months of treatment by means of the Brief Psychiatric Rating Scale (BPRS) and of the Scales for the Assessment of Positive and Negative Symptoms of Schizophrenia. Non-responders to risperidone were then treated with clozapine (up to 600 mg/day) for the next month.

Seven patients responded to risperidone (improvement over 20 per cent in each rating scale, BPRS total score below 35), while five risperidone non-responders or partial responders improved dramatically after following clozapine treatment. Results suggest that heterogeneity in response to atypical antipsychotics may overshadow a heterogeneity in underlying biological factors.

πŸ“œ SIMILAR VOLUMES

The sequential treatment approach to res
The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up
✍ R. Cavallaro; P. Brambilla; E. Smeraldi πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 123 KB πŸ‘ 2 views

In this paper we extend and test with long-term follow-up the results of a previous paper on the usefulness of a sequential treatment protocol with risperidone and clozapine in resistant schizophrenia. Twenty-four patients diagnosed as resistant schizophrenics according to DSM III R and Kane et al.

Effectiveness of antipsychotic polypharm
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone
✍ Takefumi Suzuki; Hiroyuki Uchida; Koichiro Watanabe; Shinichiro Nakajima; Kensuk πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 89 KB πŸ‘ 2 views

## Abstract ## Objective To evaluate the effectiveness of antipsychotic polypharmacy in a methodologically sound manner. ## Methods In this open‐label study, 17 patients with treatment‐refractory schizophrenia, who failed to respond to a sequential monotherapy with olanzapine, quetiapine and ris

Long-term sustained benefits of clozapin
Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: A retrospective study in Korean children and adolescents
✍ Yeni Kim; Boong-Nyun Kim; Soo-Churl Cho; Jae-Won Kim; Min-Sup Shin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 89 KB

## Abstract Objective: Treatment resistance in early onset schizophrenia (EOS) is one of the most challenging problems in child and adolescent psychiatry. We retrospectively examined the therapeutic dosage, clinical response, and side effect profiles of long‐term clozapine treatment in Korean child

Comparison between risperidone, olanzapi
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study
✍ Rael D. Strous; Marina Kupchik; Suzana Roitman; Sima Schwartz; Noach Gonen; Robe πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 99 KB

## Abstract Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia. While they offer advantages with regard to clinical efficacy and side‐effect profile, few studies have compared them in a naturalistic prospectiv